Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

ABBV

AbbVie (ABBV)

AbbVie Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next >>

Date	Time	Source	Headline	Symbol	Company
07/20/2023	3:09PM	Dow Jones News	AbbVie on Pace for Largest Percent Increase Since June 2022 -- Data Talk	NYSE:ABBV	AbbVie Inc
07/17/2023	7:30AM	IH Market News	Monday’s Wall Street Highlights: Microsoft, Santander, Tesla, Chewy, and more	NYSE:ABBV	AbbVie Inc
07/10/2023	5:04PM	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NYSE:ABBV	AbbVie Inc
07/06/2023	4:18PM	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ABBV	AbbVie Inc
07/06/2023	8:00AM	PR Newswire (US)	AbbVie to Host Second-Quarter 2023 Earnings Conference Call	NYSE:ABBV	AbbVie Inc
06/29/2023	5:00PM	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ABBV	AbbVie Inc
06/28/2023	5:01PM	Edgar (US Regulatory)	Annual Report of Employee Stock Plans (11-k)	NYSE:ABBV	AbbVie Inc
06/28/2023	5:00PM	Edgar (US Regulatory)	Form 11-K - Annual report of employee stock purchase, savings and similar plans	NYSE:ABBV	AbbVie Inc
06/27/2023	7:48PM	Dow Jones News	AbbVie, Genmab Need Further Follow Up on Trial for Follicular Lymphoma Treatment	NYSE:ABBV	AbbVie Inc
06/27/2023	6:50PM	PR Newswire (US)	AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)	NYSE:ABBV	AbbVie Inc
06/26/2023	8:00AM	PR Newswire (US)	AbbVie Employees Volunteer During 8th Annual "Week of Possibilities" to Support Communities Globally	NYSE:ABBV	AbbVie Inc
06/23/2023	8:58AM	Dow Jones News	AbbVie Gets Positive CHMP Opinion For Migraine Treatment	NYSE:ABBV	AbbVie Inc
06/23/2023	8:04AM	PR Newswire (US)	AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine	NYSE:ABBV	AbbVie Inc
06/22/2023	1:13PM	PR Newswire (US)	AbbVie Declares Quarterly Dividend	NYSE:ABBV	AbbVie Inc
06/15/2023	8:45AM	PR Newswire (US)	Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients	NYSE:ABBV	AbbVie Inc
06/13/2023	8:45AM	PR Newswire (US)	BOTOX® Cosmetic (onabotulinumtoxinA) Announces the Winners of the IFundWomen Grant Program	NYSE:ABBV	AbbVie Inc
06/09/2023	4:03PM	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NYSE:ABBV	AbbVie Inc
06/09/2023	10:39AM	Dow Jones News	NY AG Lands Final Approval for $17.3 Billion Opioid Settlement	NYSE:ABBV	AbbVie Inc
06/09/2023	3:00AM	PR Newswire (US)	AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients	NYSE:ABBV	AbbVie Inc
06/07/2023	7:01AM	PR Newswire (Canada)	AbbVie Announces Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia under the Non-Insured Health Benefits (NIHB) Program	NYSE:ABBV	AbbVie Inc
06/07/2023	7:01AM	PR Newswire (Canada)	AbbVie annonce le remboursement de VRAYLAR® (cariprazine) pour le traitement de la schizophrénie en vertu du Programme des services de santé non assurés (SSNA)	NYSE:ABBV	AbbVie Inc
06/06/2023	8:00AM	PR Newswire (US)	AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference	NYSE:ABBV	AbbVie Inc
06/01/2023	2:59AM	Dow Jones News	AstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development Program	NYSE:ABBV	AbbVie Inc
05/31/2023	2:30AM	PR Newswire (US)	Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus	NYSE:ABBV	AbbVie Inc
05/25/2023	8:45AM	PR Newswire (US)	New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease	NYSE:ABBV	AbbVie Inc
05/24/2023	9:00AM	PR Newswire (US)	AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress	NYSE:ABBV	AbbVie Inc
05/19/2023	12:34PM	PR Newswire (US)	EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	NYSE:ABBV	AbbVie Inc
05/18/2023	1:55PM	Dow Jones News	AbbVie Gets FDA Expanded Nod for Rinvoq in Crohn's Disease	NYSE:ABBV	AbbVie Inc
05/18/2023	12:25PM	PR Newswire (US)	U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults	NYSE:ABBV	AbbVie Inc
05/15/2023	8:45AM	PR Newswire (US)	SKINVIVE™ by JUVÉDERM® Receives U.S. FDA Approval	NYSE:ABBV	AbbVie Inc

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next >>

Seafarer Exploration (PK)

NioCorp Developments

Therapeutic Solutions (PK)

Bell Buckle (PK)

Marketing Worldwide (PK)

Good Vibrations Shoes (PK)

Fannie Mae (QB)

Trump Media and Technology

Seven Arts Entertainment (PK)

Anavex Life Sciences

Kraig Biocraft Laborator... (QB)

Brookmount Explorations (PK)

Delayed Upgrade Clock